Syngene International Announces Q4 Results; PAT Declines 19% to Rs 148 Crore, EBITDA Margin at 30.8%

The Indian equity markets closed weak on Thursday, with the Nifty 50 index ending lower by 0.74 per cent at 23,997.55. Despite the weakness in benchmark indices, stock-specific buying momentum remained visible in select healthcare and life sciences counters. In this segment, Syngene International remained in focus after the company announced its Q4FY26 and FY26 consolidated financial results along with key management transition updates. Following the announcement, Syngene's share price closed higher by 8.21 per cent at Rs 467.65 on Thursday.

Syngene International Q4FY26 Results

Syngene reported consolidated revenue from operations of Rs 1,036.5 crore in Q4FY26 as against Rs 1,018 crore in Q4FY25, registering a growth of 1.8 per cent YoY. Reported revenue stood at Rs 1,058.7 crore compared to Rs 1,036.9 crore in the corresponding quarter last year, reflecting a growth of 2.1 per cent YoY.

EBITDA came in at Rs 325.6 crore in Q4FY26 as against Rs 362.5 crore in Q4FY25, marking a decline of 10.2 per cent YoY, while EBITDA margin moderated to 30.8 per cent from 35 per cent in the year-ago quarter.

Profit before Tax stood at Rs 202 crore compared to Rs 240.5 crore in the corresponding quarter last year, reflecting a decline of 16.0 per cent YoY. Profit after tax before exceptional items came in at Rs 153.2 crore as against Rs 183.3 crore in Q4FY25, marking a decline of 16.4 per cent YoY, while reported PAT after exceptional items stood at Rs 147.9 crore compared to Rs 183.3 crore reported in the year-ago quarter, reflecting a decline of 19.3 per cent YoY.

Syngene International FY26 Annual Performance

For the financial year ended March 31, 2026, Syngene reported consolidated revenue from operations of Rs 3,738.7 crore as against Rs 3,642.4 crore in FY25, registering a growth of 2.6 per cent YoY. Reported revenue stood at Rs 3,809.4 crore compared to Rs 3,714.2 crore in the previous financial year, reflecting a growth of 2.6 per cent YoY.

EBITDA for FY26 stood at Rs 989.1 crore compared to Rs 1,113.6 crore in FY25, reflecting a decline of 11.2 per cent YoY, while EBITDA margin narrowed to 26 per cent from 30 per cent.

Profit before tax came in at Rs 487.5 crore versus Rs 627.9 crore in FY25, reflecting a decline of 22.4 per cent YoY. Profit after tax before exceptional items stood at Rs 379.9 crore as against Rs 474.9 crore, marking a decline of 20.0 per cent YoY, while reported PAT after exceptional items declined to Rs 316.7 crore from Rs 496.2 crore in FY25, reflecting a decline of 36.2 per cent YoY.

Strategic Business and Management Developments

Syngene commenced operations at its ADC discovery laboratory during the quarter, complementing the recently added GMP bioconjugation suite and establishing end-to-end antibody drug conjugate capabilities from discovery to manufacturing.

The company also completed 14 audits during the quarter, taking the FY26 total to 85 audits, while receiving GCP-NABL accreditation and inclusion in the S&P Global Sustainability Yearbook 2026 among the top 10 life sciences companies globally.

On the management side, Kiran Mazumdar-Shaw transitioned from Non-Executive Chairperson to Executive Chairperson effective April 1, 2026. Further, Siddharth Mittal has been appointed as Managing Director and Chief Executive Officer effective July 1, 2026, succeeding Peter Bains.

About Syngene International

Syngene International Ltd is one of India’s leading integrated contract research, development and manufacturing organizations (CRDMO), offering scientific services across drug discovery, development, biologics, small molecules and commercial manufacturing. The company serves around 400 active clients globally, including 16 of the top 20 global pharma companies.

Share your thoughts in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.